Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial

Abstract Background The aim in this study was to investigate the effect of vitamin D (25(OH)D3) supplementation on heat shock protein 60 (HSP 60) and other inflammatory markers (IL-17, TNF-α, PAB) in patients with coronary heart disease (CHD). Methods In this double-blind, randomized clinical trial,...

Full description

Bibliographic Details
Main Authors: Leila Sadat Bahrami, Seyed Hashem Sezavar Seyedi Jandaghi, Leila Janani, Mina Pahlavan, Seyed Mostafa Arabi, Homa Sadeghi, Mohammadreza Vafa
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Nutrition & Metabolism
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12986-018-0292-9
id doaj-260958bd70924841bbd4a563d8f867fb
record_format Article
spelling doaj-260958bd70924841bbd4a563d8f867fb2020-11-25T00:10:08ZengBMCNutrition & Metabolism1743-70752018-08-011511910.1186/s12986-018-0292-9Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trialLeila Sadat Bahrami0Seyed Hashem Sezavar Seyedi Jandaghi1Leila Janani2Mina Pahlavan3Seyed Mostafa Arabi4Homa Sadeghi5Mohammadreza Vafa6Department of Nutrition, School of Public Health, Iran University of Medical SciencesRasool-e Akram Hospital, Iran University of Medical SciencesDepartment of Biostatistics, School of Public Health, Iran University of Medical SciencesDepartment of Medical Surgical Nursing, Nursing and Midwifery School, Iran University of Medical SciencesDepartment of Nutrition, Metabolic Syndrome Research Center, Mashhad University of Medical SciencesInstitute of Public Health and Clinical Nutrition, University of Eastern FinlandDepartment of Nutrition, School of Public Health, Iran University of Medical SciencesAbstract Background The aim in this study was to investigate the effect of vitamin D (25(OH)D3) supplementation on heat shock protein 60 (HSP 60) and other inflammatory markers (IL-17, TNF-α, PAB) in patients with coronary heart disease (CHD). Methods In this double-blind, randomized clinical trial, we recruited 80 male and female patients aged 30–60 with CHD and 25(OH)D3 serum levels < 30 ng/ml from Rasool-e-Akram Hospital in Tehran, Iran. Serum levels of HSP 60 as primary outcome, and 25(OH)D3, IL-17, TNF-α, PAB, lipid profiles and parathyroid hormone (PTH) as secondary outcomes were measured at baseline and post-intervention. We randomly assigned eligible participants to a placebo group (N = 40) or an intervention group (N = 40) (50,000 IU/wk. vitamin D supplement) for eight weeks. Results The results demonstrated that vitamin D supplementation resulted in a significant increase in 25(OH) D3 serum levels in the intervention group compared to the placebo group (46.86 vs. 7.28 ng/ml). PTH levels decreased in the intervention group compared to the placebo group (− 19.81 vs. 2.92 pg/ml) after eight weeks of supplementation. Furthermore, we observed a significant change in waist circumference (− 0.97 vs. -0.26 cm), fat percentage (−.13 vs. 0.1%), systolic blood pressure (− 3.85 vs. -2.11 mmHg) and diastolic blood presure (− 4 vs. -1.86 mmHg) in the vitamin D group compared to the placebo group (all P values < 0.05). Other variables did not significantly change after the intervention. Conclusion Based on our findings, weekly vitamin D supplementation of 50,000 IU for eight weeks in patients with CHD resulted in decreased systolic and diastolic blood pressure, waist circumference and fat percentage. No significant effect on HSP 60, inflammatory markers or lipid profiles was observed. Trial registration IRCT, IRCT201612122365N14. Registered 12 December 2016.http://link.springer.com/article/10.1186/s12986-018-0292-9Vitamin D supplementationCoronary heart diseaseHeat shock protein 60
collection DOAJ
language English
format Article
sources DOAJ
author Leila Sadat Bahrami
Seyed Hashem Sezavar Seyedi Jandaghi
Leila Janani
Mina Pahlavan
Seyed Mostafa Arabi
Homa Sadeghi
Mohammadreza Vafa
spellingShingle Leila Sadat Bahrami
Seyed Hashem Sezavar Seyedi Jandaghi
Leila Janani
Mina Pahlavan
Seyed Mostafa Arabi
Homa Sadeghi
Mohammadreza Vafa
Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
Nutrition & Metabolism
Vitamin D supplementation
Coronary heart disease
Heat shock protein 60
author_facet Leila Sadat Bahrami
Seyed Hashem Sezavar Seyedi Jandaghi
Leila Janani
Mina Pahlavan
Seyed Mostafa Arabi
Homa Sadeghi
Mohammadreza Vafa
author_sort Leila Sadat Bahrami
title Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
title_short Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
title_full Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
title_fullStr Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
title_full_unstemmed Vitamin D supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
title_sort vitamin d supplementation and serum heat shock protein 60 levels in patients with coronary heart disease: a randomized clinical trial
publisher BMC
series Nutrition & Metabolism
issn 1743-7075
publishDate 2018-08-01
description Abstract Background The aim in this study was to investigate the effect of vitamin D (25(OH)D3) supplementation on heat shock protein 60 (HSP 60) and other inflammatory markers (IL-17, TNF-α, PAB) in patients with coronary heart disease (CHD). Methods In this double-blind, randomized clinical trial, we recruited 80 male and female patients aged 30–60 with CHD and 25(OH)D3 serum levels < 30 ng/ml from Rasool-e-Akram Hospital in Tehran, Iran. Serum levels of HSP 60 as primary outcome, and 25(OH)D3, IL-17, TNF-α, PAB, lipid profiles and parathyroid hormone (PTH) as secondary outcomes were measured at baseline and post-intervention. We randomly assigned eligible participants to a placebo group (N = 40) or an intervention group (N = 40) (50,000 IU/wk. vitamin D supplement) for eight weeks. Results The results demonstrated that vitamin D supplementation resulted in a significant increase in 25(OH) D3 serum levels in the intervention group compared to the placebo group (46.86 vs. 7.28 ng/ml). PTH levels decreased in the intervention group compared to the placebo group (− 19.81 vs. 2.92 pg/ml) after eight weeks of supplementation. Furthermore, we observed a significant change in waist circumference (− 0.97 vs. -0.26 cm), fat percentage (−.13 vs. 0.1%), systolic blood pressure (− 3.85 vs. -2.11 mmHg) and diastolic blood presure (− 4 vs. -1.86 mmHg) in the vitamin D group compared to the placebo group (all P values < 0.05). Other variables did not significantly change after the intervention. Conclusion Based on our findings, weekly vitamin D supplementation of 50,000 IU for eight weeks in patients with CHD resulted in decreased systolic and diastolic blood pressure, waist circumference and fat percentage. No significant effect on HSP 60, inflammatory markers or lipid profiles was observed. Trial registration IRCT, IRCT201612122365N14. Registered 12 December 2016.
topic Vitamin D supplementation
Coronary heart disease
Heat shock protein 60
url http://link.springer.com/article/10.1186/s12986-018-0292-9
work_keys_str_mv AT leilasadatbahrami vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
AT seyedhashemsezavarseyedijandaghi vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
AT leilajanani vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
AT minapahlavan vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
AT seyedmostafaarabi vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
AT homasadeghi vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
AT mohammadrezavafa vitamindsupplementationandserumheatshockprotein60levelsinpatientswithcoronaryheartdiseasearandomizedclinicaltrial
_version_ 1725409143730208768